Bulletin
Investor Alert

New York Markets Close in:

Mirati Therapeutics Inc.

NAS: MRTX

GO
/marketstate/country/us

Countdown to close

/zigman2/quotes/209009887/composite

$

92.95

Change

-3.31 -3.43%

Volume

Volume 952,913

Dec 5, 2022, 3:54 p.m.

Real time quotes

/zigman2/quotes/209009887/composite

Previous close

$ 96.25

$ 92.95

Change

-3.31 -3.43%

Day low

Day high

$88.69

$96.47

Open
Open: 96.21

52 week low

52 week high

$32.96

$154.17

Open

Market cap

$5.54B

Average volume

1.05M

P/E ratio

N/A

Rev. per Employee

$28,232

EPS

-13.38

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/mrtx

MarketWatch News on MRTX

  1. Horizon Therapeutics Surges on Takeover Talk

    11:14 a.m. Nov. 30, 2022

    - Barron's Online

  2. Mirati Therapeutics started at neutral with $72 stock price target at B. Riley

    7:43 a.m. Oct. 28, 2022

    - Tomi Kilgore

  3. Mirati Therapeutics stock price target cut to $94 from $109 at J.P. Morgan

    5:16 a.m. Sept. 26, 2022

    - Tomi Kilgore

  4. Seven reasons the beleaguered biotech sector is now a ‘buy’

    7:43 a.m. June 21, 2022

    - Michael Brush

  5. Mirati Therapeutics stock price target cut to $105 from $133 at Stifel Nicolaus

    5:53 a.m. May 27, 2022

    - Tomi Kilgore

  6. Mirati Therapeutics started at outperform with $187 stock price target at BMO Capital

    8:51 a.m. Nov. 19, 2021

    - Tomi Kilgore

  7. Mirati Therapeutics started at buy with $202 stock price target at Stifel Nicolaus

    6:42 a.m. Sept. 23, 2021

    - Tomi Kilgore

  8. Mirati Therapeutics started at equal weight at Morgan Stanley

    8:53 a.m. Aug. 26, 2021

    - Tomi Kilgore

  9. 5 Biopharma Stocks That Are Cheap and Growing

    6:00 a.m. May 20, 2021

    - Barron's Online

  10. Mirati Therapeuticsw downgraded to perform from outperform at Oppenheimer

    6:55 a.m. May 17, 2021

    - Tomi Kilgore

  11. Barnes & Noble Education and MobileIron See Activist Action

    9:30 p.m. Nov. 6, 2020

    - Barron's Online

  12. Amgen Sales Show How a Biotech Can Thrive on Biosimilars

    5:51 p.m. Oct. 28, 2020

    - Barron's Online

  13. Mirati Therapeutics stock price target raised to $195 from $134 at SVB Leerink

    6:14 a.m. Oct. 26, 2020

    - Tomi Kilgore

  14. Cancer Meeting Could Ignite These Biotech Stocks

    5:00 a.m. Oct. 24, 2020

    - Barron's Online

  15. Amgen Says Study Results on Its Novel Cancer Drug Were Positive

    5:20 p.m. Oct. 6, 2020

    - Barron's Online

  16. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/mrtx

Other News on MRTX

  1. Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

    10:22 a.m. Nov. 24, 2022

    - Zacks.com

  2. Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

    5:25 p.m. Nov. 8, 2022

    - Zacks.com

  3. Tracking Baker Brothers Portfolio - Q2 2022 Update

    7:51 p.m. Sept. 28, 2022

    - Seeking Alpha

  4. Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer

    12:36 p.m. Sept. 15, 2022

    - Seeking Alpha

  5. Verastem: Moving Forward

    7:14 a.m. Sept. 13, 2022

    - Seeking Alpha

  6. New Cancer Drug Beats Chemotherapy in Study

    1:33 a.m. Sept. 13, 2022

    - The Wall Street Journal Interactive Edition

  7. 3 Stocks Expecting Good News From the FDA

    6:37 a.m. Sept. 12, 2022

    - Motley Fool

  8. Mirati: A Potential Blockbuster Stock, Will Need Patience

    2:42 p.m. Sept. 8, 2022

    - Seeking Alpha

  9. Mirati jumps 11% as Amgen meets key goal for rival cancer drug

    5:49 a.m. Aug. 31, 2022

    - Seeking Alpha

  10. Loading more headlines...
/news/pressrelease/company/us/mrtx

Press Releases on MRTX

  1. Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

    8:00 a.m. Dec. 2, 2022

    - PR Newswire - PRF

  2. Wednesday's ETF with Unusual Volume: IYH

    11:03 a.m. Aug. 31, 2022

    - MarketNewsVideo.com

  3. Loading more headlines...

Rates »

Link to MarketWatch's Slice.